ZEISS India Strengthens Portfolio with the Launch of ZEISS ClearMind Lenses

▴ ZEISS India
Introducing are first-of-its-kind ZEISS prescription lenses to provide extremely clear vision designed to reduce cognitive load.

National, 1st April: ZEISS, a pioneer of science in optics announces the launch its latest prescription lenses ZEISS ClearMind lenses in India. The all-day lenses addition to the lens portfolio delivers clear vision while reducing cognitive load due to blur for daily eyeglass wearers. For eye care professionals this offering elevates their practice with advanced lens technology that supports both visual performance and comfort.

 

In today’s fast-paced world with countless visual stimuli to process, there is an increase in information overload where individuals may feel overwhelmed. With pre-existing conditions of blur on spectacle lenses, the ability to identify and interpret complex stimuli is compromised. ZEISS ClearMind lenses are built on a unique design that reduces and smooths optical errors, increasing the clear vision zones and reducing peripheral lens blur thus reducing cognitive load.

 

Commenting on the addition to the lens portfolio, Rohan Paul, Business Head – India & Neighboring Markets, Vision Care, ZEISS India, said, “At ZEISS, innovation is at the core of everything we do. We are committed to protecting vision & visual health of world’s consumers. The launch of ZEISS ClearMind lenses reflects our continued focus on developing advanced optical solutions that enable individuals to see better, clearer and experience better comfort in their daily lives. We look forward to the positive impact these lenses will have, in collaboration with our valued business partners, as we continue to reach individuals seeking effective and personalized eye care solutions.”

 

Benefits of ZEISS ClearMind lenses at a glance

  • ZEISS ClearMind is a new, premium, all-day lens portfolio with larger zones of clear vision  embedded with ZEISS NeurOptix technology
  • In consumer studies, 96 % of wearers confirmed extremely clear vision. 9 out of 10 wearers also experienced less cognitive load in a blind test compared to a standard ZEISS progressive lens
  • The lenses are available for all age groups to promote perceived overall well-being, and good vision

 

Backed by scientific research to reduce cognitive load

Research conducted at the ZEISS Vision Science Lab (Tübingen University, Germany) established a direct connection between lens-induced blur and increased cognitive load. In consumer studies, 96% of wearers reported extremely clear vision when using ZEISS ClearMind lenses. 9 out of 10 wearers experienced reduced cognitive load compared to standard progressive lenses. Many wearers also reported an improvement in overall well-being while using the lenses. They also highlighted the importance of comfortable vision while staying focused for long hours.

 

 

Embedded with ZEISS NeurOptix technology for improved visual clarity

By aligning lens clarity zones to natural eye-movement patterns, ZEISS NeurOptix technology aims to reduce the brain’s cognitive load, provide more relaxed, effortless vision, as well as improve comfort during long days of digital, visually busy and dynamic activity. As a result, ZEISS Progressive ClearMind lenses offer up to 41% larger near-vision zones compared to ZEISS SmartLife progressive lenses. The technology also supports fast adaptation. 88% of wearers adjust within a few days, and over half within just an hour.

 

All-day lens portfolio includes single vision, progressive and digital focal types

ZEISS Single Vision ClearMind lenses are designed for 18+ wearers with blurry vision near or far. They reduce peripheral blur and provide larger clear vision zones than standard ZEISS lenses. ZEISS Digital ClearMind lenses are made for 35+ wearers experiencing blurry vision and tired eyes. They reduce blur and offer larger vision zones than ZEISS Digital SmartLife lenses. The design supports natural viewing habits and ensures smooth transition to near vision. It also enables an easier shift to progressive lenses in the future. ZEISS Progressive ClearMind lenses are designed for 45+ wearers with presbyopia. They reduce and optimize peripheral blur, creating wider clear vision zones than ZEISS SmartLife progressive lenses. They support smooth transitions across distances and improve overall visual flow.

 

For more details on ZEISS ClearMind lenses, Please visit ZEISS ClearMind At a Glance

About ZEISS Group:

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets.

 

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

 

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

 

With around 46,600 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026
Fatty Liver Disease: Connecting Metabolic Health With Liver CareNovember 12, 2026
Chronic Kidney Disease: Understanding Risk Assessment and Early MonitoringNovember 12, 2026
Advanced OCTA Diagnostics in Age-Related Macular Degeneration (AMD)November 11, 2026
Advanced Diagnostics in Age-Related Macular Degeneration (AMD): Optical Coherence Tomography Angiography (OCTA)November 11, 2026
PCOS Care in India: Understanding Diagnosis and Long-Term MonitoringNovember 11, 2026
Thyroid Health: Making Sense of Testing and Follow-UpNovember 11, 2026